verified SJR 1,884 · Q1 • database Scopus / SJR & Web of Science indexed

Switzerland

workspace_premium Q1 — Neurology (clinical) lock Subscription

CNS Drugs

CNS Drugs is a journal indexed in SJR in Neurology (clinical) and Psychiatry and Mental Health with an H index of 132. It has a price of 3190 €. It has an SJR impact factor of 1,884 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 1,884.

CNS Drugs focuses its scope in these topics and keywords: comprehensive, treatment, valproatecalcitonin, orthostatic, reviewpregabalin, reviewmedication, reviewmanagement, pathophysiology, neurobiological, antidepressant, ...

ISSN: 1172-7047

Category: Neurology (clinical)

Indexation: verifiedScopus / SJR verifiedWeb of Science

open_in_new Portal NPD menu_book Guidelines NPD

schedule CountryOfPapers database fields

SJR Impact Factor trending_up

1,884 Q1

H-index 132

Acceptance rate pie_chart

23% Selective

Source Acceptance_Rate

Time to publication hourglass_top

NPD

Field NPD

Publication cost (APC) payments

3.190 € Subscription

Non-OA path 0 €

Metrics

Scimago and CountryOfPapers database fields

Scopus / SJR Web of Science

SJR Impact

1,884

H-index

132

Docs (year)

Docs 3y

252

Total refs

5744

Cites 3y

1647

Citable 3y

240

Cites/Doc 2y

6.84

Ref/Doc

78.68

Immediate OA

3190 €

Embargoed OA

NPD

Non OA / Submission

0 €

shield Researcher voice

Name good journals. Call out predatory ones.

Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.

Fair & fast peer review Clear APC / no surprise fees Suspected predatory Fake impact claims

rate_review Write an honest review

Researcher reviews

sentiment_dissatisfied No reviews yet — be the first to share an honest experience.

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID * * Only to validate authenticity — identity is not shown publicly.

Best articles by citations

CNS Nicotinic Receptors

Zolpidem Extended-Release

Efficacy and Safety of Intravenous Valproate for Status Epilepticus: A Systematic Review

Effectiveness of Lithium in Children and Adolescents with Conduct Disorder

Drug-Induced Delirium

Drug-Induced Cerebellar Ataxia: A Systematic Review

Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: A Network Meta-Analysis

Discontinuation Syndrome Associated with Paroxetine in Depressed Patients

Current Issues in the Treatment of Acute Posterior Circulation Stroke

CSF Penetration by Antiretroviral Drugs

Cost Effectiveness of Fingolimod, Teriflunomide, Dimethyl Fumarate and Intramuscular Interferon-beta1a in Relapsing-Remitting Multiple Sclerosis

Compliance and Outcome in Patients Treated with Antipsychotics

SHOW MORE ARTICLES

Comment on: "Perispinal Etanercept for Post-Stroke Neurological and Cognitive Dysfunction: Scientific Rationale and Current Evidence"

A Focused Systematic Review of Pharmacological Treatment for Borderline Personality Disorder

Clinically Significant Drug Interactions with Newer Antidepressants

Clinical Implications of CNS Penetration of Antiretroviral Drugs

Cardiovascular Effects of Stimulant and Non-Stimulant Medication for Children and Adolescents with ADHD: A Systematic Review and Meta-Analysis of Trials of Methylphenidate, Amphetamines and Atomoxetine

Biomarkers of Response to Smoking Cessation Pharmacotherapies: Progress to Date

Assessing Therapeutic Efficacy in a Progressive Disease

Aripiprazole

Antimicrobial Use in Patients with Dementia: Current Concerns and Future Recommendations

Amyotrophic Lateral Sclerosis

Advances in Drug Treatments for Children and Adolescents with Autism and Other Pervasive Developmental Disorders

Activities of Daily Living in Patients with Dementia

FAQs

CNS Drugs has an SJR of 1,884 (best quartile Q1) in the CountryOfPapers database.

Immediate OA APC is 3190 EUR. Non-OA / submission fee is 0 EUR.

The acceptance rate recorded for CNS Drugs is 23%.

CNS Drugs

Metrics

Name good journals. Call out predatory ones.

Researcher reviews

Best articles by citations

FAQs

What is the SJR of CNS Drugs?

What is the APC / publication cost?

What is the acceptance rate?